Joanne LaFleur1, Linda S Tyler, Rajiv R Sharma. 1. Pharmacotherapy Outcomes Research Center, College of Pharmacy, University of Utah, 30 S. 2000 East, Room 258, Salt Lake City, UT 84112-0582, USA. joanne.lafleur@hsc.utah.edu
Abstract
PURPOSE: The drug cost avoidance and revenue associated with the provision of investigational drug services (IDSs) at an academic institution were studied. METHODS: The study protocols and dispensing data for the investigational drug studies conducted at the institution over two fiscal years (2000-01 and 2001-02) were reviewed. Revenue generated was calculated for all studies, and drug cost avoidance was calculated for studies in which patients were likely to have been treated with active drug had they not been included in the study. RESULTS: Of 139 studies in which the IDS was involved, 107 (77%) were eligible for the cost avoidance analysis. The total drug cost avoidance plus revenue over the two fiscal years was $5,300,428. The annualized drug cost avoidance plus revenue was $2.6 million. Cost avoidance varied with the type of study and the disease category involved. CONCLUSION: An IDS accounted for substantial drug cost avoidance over two fiscal years.
PURPOSE: The drug cost avoidance and revenue associated with the provision of investigational drug services (IDSs) at an academic institution were studied. METHODS: The study protocols and dispensing data for the investigational drug studies conducted at the institution over two fiscal years (2000-01 and 2001-02) were reviewed. Revenue generated was calculated for all studies, and drug cost avoidance was calculated for studies in which patients were likely to have been treated with active drug had they not been included in the study. RESULTS: Of 139 studies in which the IDS was involved, 107 (77%) were eligible for the cost avoidance analysis. The total drug cost avoidance plus revenue over the two fiscal years was $5,300,428. The annualized drug cost avoidance plus revenue was $2.6 million. Cost avoidance varied with the type of study and the disease category involved. CONCLUSION: An IDS accounted for substantial drug cost avoidance over two fiscal years.
Authors: Sebastián García-Sánchez; Roberto Collado-Borrell; Eva González-Haba; José Luis Revuelta-Herrero; Vicente Escudero-Vilaplana; María Belén Marzal-Alfaro; María Norberta Sánchez-Fresneda; Ana Mur-Mur; Ana Herranz; Miguel Martín; María Sanjurjo Journal: Front Oncol Date: 2022-06-08 Impact factor: 5.738
Authors: Zoltán Kaló; János Antal; Miklós Pénzes; Csilla Pozsgay; Zsuzsanna Szepezdi; László Nagyjánosi Journal: Croat Med J Date: 2014-10 Impact factor: 1.351
Authors: Domingo Antonio Sánchez Martínez; Federico Salas-Lucia; Hanzi Jiang; Paula Ruiz-Carreño; José Luis Alonso Romero Journal: BMC Health Serv Res Date: 2022-07-26 Impact factor: 2.908
Authors: Francesca D'Ambrosio; Gianfranco De Feo; Gerardo Botti; Arturo Capasso; Sandro Pignata; Piera Maiolino; Maria Triassi; Antonio Nardone; Franco Perrone; Michela Piezzo; Antonio Maria Grimaldi; Ida Palazzo; Immacolata De Stasio; Roberta D'Aniello; Alessandro Morabito; Giacomo Pascarella Journal: BMC Health Serv Res Date: 2020-11-26 Impact factor: 2.655